Medical Research • Psychedelics Science

Ibogaine for Addiction: What the Evidence Shows

Iboga Shrub scaled
Written by Jason Collins

People who have struggled with opioid addiction for years describe a single, long, difficult ibogaine session that wiped out their withdrawal and, for some, their cravings. Veterans describe relief from trauma that nothing else gave them. In 2026, that reputation reached the White House.

Ibogaine also has a documented danger: it can disturb the heart’s rhythm, and people have died after taking it. And the evidence for its benefits comes almost entirely from studies without a placebo group. Here is what the research shows.

What is ibogaine?

Ibogaine is an alkaloid from the root bark of Tabernanthe iboga, a shrub of the Central African rainforest whose bark is central to Bwiti initiation ceremonies in Gabon[1]. A related compound from the Voacanga africana tree can be converted into ibogaine for commercial supply[2].

The body turns ibogaine into noribogaine, which is also active and stays in the body for days: in healthy volunteers, its half-life was 28 to 49 hours[3]. That may help explain why effects outlast the session.

Its anti-addictive reputation dates to 1962, when a small group of drug experimenters in New York, including Howard Lotsof, noticed that heroin-dependent people who took ibogaine had no withdrawal symptoms[4]. A decade later, Hunter S. Thompson satirically suggested in Rolling Stone that presidential candidate Edmund Muskie was on “some kind of strange drug” called ibogaine[5].

How does ibogaine work?

Unlike classic psychedelics such as psilocybin, whose psychedelic effects are driven mainly by the 5-HT2A serotonin receptor, ibogaine touches many targets, each fairly weakly. It blocks NMDA receptors (the same target as ketamine) and certain nicotinic receptors involved in opioid withdrawal, while noribogaine activates kappa-opioid receptors and blocks serotonin reuptake. Cell and animal studies suggest both may also alter growth-factor signaling, such as GDNF and BDNF[6]. In rats, a single dose produced an antidepressant-like effect[7]. And ibogaine blocks hERG potassium channels in the heart, which can prolong the QT interval, the problem that shadows everything else[6]. For the ketamine comparison, see our review of ketamine for depression.

What do studies in people show?

Most of the human evidence comes from people who sought treatment on their own at private clinics, mostly in Mexico, and agreed to be followed up.

Opioid addiction. Among 30 people treated at two Mexican clinics, withdrawal scores fell from 31 to 14, half reported no opioid use a month later, and drug use stayed below baseline for up to a year in some[8]. A New Zealand study of 14 people found similar long-term drops in addiction severity and depression[9]. In a survey of 88 former patients of a Mexican detox program, 80% said withdrawal was eliminated or drastically reduced, though 70% relapsed at some point[10]. All three teams cautioned that their designs could not prove ibogaine caused the improvement.

Veterans. The study that brought ibogaine into the mainstream came from Stanford in 2024. Thirty male special operations veterans, most with mild traumatic brain injury, received ibogaine with intravenous magnesium at a clinic in Mexico. A month later, disability scores had fallen from 30.2 to 5.1, with large improvements in PTSD, depression and anxiety, and no serious adverse events[11]. But the study had no placebo group, the veterans chose the treatment themselves, and the clinic program was more than ibogaine: it typically included 5-MeO-DMT a few days later, plus voluntary coaching before and after[12]. In a 2026 follow-up, 25 participants completed assessments at 12 months, and the improvements remained large. But 23 had used at least one other psychedelic during the intervening months and 12 had received therapy or counseling, so the lasting changes cannot be attributed to ibogaine alone[12].

Has ibogaine been tested against a placebo?

Barely. A 2022 review of 24 clinical studies found two randomized, double-blind trials, both of noribogaine rather than ibogaine, and one small double-blind trial of ibogaine in 20 people with cocaine dependence, which reported reduced craving[13]. In the noribogaine trial in 27 opioid-dependent patients, withdrawal showed only a non-significant trend toward improvement, while the QT interval lengthened with dose[14]. Our own searches in November 2026 found no adequately powered, placebo-controlled efficacy trial of ibogaine for opioid use disorder. That is the gap the new government-funded trials are meant to fill. It also matters for context: methadone and buprenorphine are each associated with substantially lower death rates while people stay in treatment[15], whereas ibogaine has not been shown in randomized trials to reduce overdose or mortality.

Is ibogaine dangerous?

Yes. Careful screening and continuous cardiac monitoring can reduce the risk, but they do not make ibogaine safe. In a Dutch hospital study of 14 people with opioid dependence given a single 10 mg/kg dose, half developed a QTc interval above 500 milliseconds, a level linked to dangerous arrhythmias, and all had temporary, severe loss of coordination. The authors concluded ibogaine belongs only in well-controlled settings with strict cardiac monitoring[16].

A forensic review identified 19 deaths between 1990 and 2008 within days of taking ibogaine, most during opioid detox; heart disease or other drugs contributed to death in 12 of the 14 cases with adequate autopsy data[17]. One participant in the New Zealand study died during treatment, most likely from an arrhythmia[9]. A 2026 preprint, not yet peer reviewed, found six deaths among 19,071 patients at 11 clinics, all in people being treated for opioid use disorder, and none among 8,689 treated for other conditions[18]. Because the data were supplied retrospectively by the clinics that chose to take part and the deaths were not independently adjudicated, the authors cautioned that their mortality estimate is probably a lower bound[18].

Reported deaths are concentrated in opioid-detoxification settings, particularly when heart disease or other drugs are also involved[17, 18]. The FDA also lists low potassium, calcium or magnesium, a slow heart rate and other QT-prolonging medications as risk factors for dangerous arrhythmias[19]. The Stanford protocol used magnesium, screening and cardiac monitoring[11]. Practices at private clinics vary, and the FDA is considering substantially stricter safeguards for US trials: an inpatient telemetry unit, a defibrillator at the bedside, a team trained in advanced cardiac life support, and monitoring that could last 36 hours or longer[19]. For more on psychedelic side effects, see our brief on adverse effects in a national survey.

Is ibogaine legal?

In the United States, ibogaine is a Schedule I controlled substance[20], which is why many American patients have traveled to clinics in Mexico[8, 11]. In New Zealand, ibogaine is an unapproved prescription-only medicine that an authorized prescriber may supply; it is not an approved addiction treatment[21]. Gabon temporarily halted iboga exports in 2026 while developing rules intended to protect wild supplies and secure a fairer share of the benefits[1].

Why are governments now funding ibogaine research?

  • Kentucky proposed spending $42 million of opioid settlement money on ibogaine research in 2023, then backed away after a cardiologist called it unsafe and unproven[22].
  • Texas committed $50 million in 2025 to clinical trials aimed at FDA approval[23], and in March 2026 said it would run its own research program after no drug company submitted a proposal that met state requirements[24].
  • The federal government followed with an executive order, “Accelerating Medical Treatments for Serious Mental Illness,” signed on April 18, 2026, which directs federal agencies to support ibogaine research and FDA review[25]. The FDA has also allowed an early-phase US study of noribogaine for alcohol use disorder to proceed[26]. In October, the FDA opened a request for information on the design of federally supported early-phase ibogaine trials, for opioid use disorder and PTSD. It proposed that initial studies start no higher than 10 mg/kg and sought comment on extended cardiac monitoring and other safeguards. Comments are open through November 20, 2026[19, 26].

For the wider context, see our article on psychedelics for the treatment of substance use disorder.

The short version

In observational studies, people treated for opioid addiction reported dramatically easier withdrawal and, for some, lasting reductions in drug use, and veterans reported large improvements in PTSD and depression. But almost none of this evidence is placebo-controlled, and ibogaine’s effect on the heart is real: deaths have occurred, particularly in opioid-detoxification settings and among people with cardiac or other medical risk factors. Ibogaine may yet prove to be a breakthrough. The honest answer in November 2026 is that ibogaine has a strong observational signal, a credible biological rationale and a serious safety problem, but still no adequately powered randomized evidence that it produces lasting recovery from opioid addiction. The carefully monitored trials now being planned are how we will find out.

References

  1. Helfend M. Gabon, home to the medicinal plant behind ibogaine, wants a fairer share of its global boom. Mongabay. 1 October 2026.
  2. González B, Fagúndez C, Peixoto de Abreu Lima A, et al. Efficient access to the iboga skeleton: optimized procedure to obtain voacangine from Voacanga africana root bark. ACS Omega. 2021;6(26):16755-16762.
  3. Glue P, Lockhart M, Lam F, et al. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2015.
  4. Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115(1):9-24.
  5. Thompson HS. Fear and Loathing on the Campaign Trail ’72. Straight Arrow Books; 1973.
  6. Ona G, Reverte I, Rossi GN, et al. Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: a mechanistic overview. J Psychopharmacol. 2023.
  7. Rodríguez P, Urbanavicius J, Prieto JP, et al. A single administration of the atypical psychedelic ibogaine or its metabolite noribogaine induces an antidepressant-like effect in rats. ACS Chem Neurosci. 2020;11(11).
  8. Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. Published online 2017.
  9. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. Published online 2017.
  10. Davis AK, Barsuglia JP, Windham-Herman AM, et al. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. J Psychedelic Stud. 2017.
  11. Cherian KN, Keynan JN, Anker L, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nat Med. 2024.
  12. Faerman A, Lissemore JI, et al. Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in Special Operations Veterans with traumatic brain injuries. Transl Psychiatry. 2026.
  13. Köck P, Frölich K, Walter M, et al. A systematic literature review of clinical trials and therapeutic applications of ibogaine. J Subst Abuse Treat. 2022;138:108717.
  14. Glue P, Cape G, Tunnicliff D, et al. Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clin Pharmacol Drug Dev. 2016.
  15. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
  16. Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction. Published online 2021.
  17. Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57(2):398-410.
  18. Arns M, Shinozuka K, Barsuglia J. Indication-stratified mortality risk of ibogaine treatment under contemporary safety protocols: a multisite analysis of 19,071 patients and updated systematic review of fatalities. Preprint, not peer reviewed. Research Square. 17 June 2026.
  19. Food and Drug Administration. Design and safety considerations for clinical trials involving ibogaine drug products; request for information. Federal Register. 2026;91:63563. Docket FDA-2026-N-10429. 6 October 2026.
  20. US Drug Enforcement Administration. Schedules of controlled substances: Schedule I, hallucinogenic substances, ibogaine (code 7260). 21 CFR §1308.11(d)(21).
  21. Thomas C (Health and Disability Commissioner). Clear rules for prescribers must be adhered to when medicines sit at the margin. NZ Doctor. September 2015.
  22. NPR. Kentucky backs away from plan to fund opioid treatment research with settlement money. 7 January 2024.
  23. Texas Tribune. Texas will invest $50 million in ibogaine research. Texas Tribune. 11 June 2025.
  24. Office of the Lieutenant Governor of Texas. Lt. Gov. Dan Patrick and Speaker Dustin Burrows joint statement on ibogaine program progress. 31 March 2026.
  25. The White House. President Trump’s landmark order advances breakthrough mental health treatments, delivering new hope to veterans. 20 April 2026.
  26. US Food and Drug Administration. FDA seeks public input to support ibogaine research. Press announcement, 5 October 2026.

This article is an educational summary of published research. It is not medical advice, and it does not recommend any clinic or treatment. Ibogaine is a Schedule I controlled substance in the United States and can cause life-threatening heart rhythm problems.

Editor’s note: Originally published February 2022 by Jason Collins as “The Iboga Shrub: Its Uses and Effects”; rewritten and expanded November 2026 with human study results, safety data and policy developments. This page also replaces our earlier partner article “Ibogaine: The Strange Kind of Drug for Transcending Addiction” (2021).

Photo: Marco Schmidt[1], CC BY-SA 2.5, via Wikimedia Commons

Last updated: November 2026.

About the author

Jason Collins

Leave a Comment